State Street’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $136M | Buy |
17,708,103
+1,252,400
| +8% | +$8.57M | ﹤0.01% | 1191 |
|
|
2025
Q4 | $32.6M | Buy |
16,455,703
+5,139,890
| +45% | +$11.6M | ﹤0.01% | 1991 |
|
|
2025
Q3 | $27.8M | Buy |
11,315,813
+3,700,247
| +49% | +$9.53M | ﹤0.01% | 2063 |
|
|
2025
Q2 | $20.1M | Buy |
7,615,566
+31,665
| +0.4% | +$85.1K | ﹤0.01% | 2177 |
|
|
2025
Q1 | $22.8M | Sell |
7,583,901
-2,201,256
| -22% | -$6.67M | ﹤0.01% | 2065 |
|
|
2024
Q4 | $25.1M | Buy |
9,785,157
+1,130,697
| +13% | +$4.71M | ﹤0.01% | 2098 |
|
|
2024
Q3 | $32.2M | Buy |
8,654,460
+790,408
| +10% | +$3.66M | ﹤0.01% | 1927 |
|
|
2024
Q2 | $49.7M | Sell |
7,864,052
-6,320,225
| -45% | -$41.7M | ﹤0.01% | 1685 |
|
|
2024
Q1 | $76.2M | Buy |
14,184,277
+4,713,368
| +50% | +$21.3M | ﹤0.01% | 1484 |
|
|
2023
Q4 | $47.5M | Buy |
9,470,909
+6,751,317
| +248% | +$21.2M | ﹤0.01% | 1729 |
|
|
2023
Q3 | $4.6M | Sell |
2,719,592
-57,644
| -2% | -$116K | ﹤0.01% | 2958 |
|
|
2023
Q2 | $7.72M | Buy |
2,777,236
+127,423
| +5% | +$360K | ﹤0.01% | 2781 |
|
|
2023
Q1 | $4.82M | Sell |
2,649,813
-4,086,238
| -61% | -$12.7M | ﹤0.01% | 3004 |
|
|
2022
Q4 | $34.2M | Buy |
6,736,051
+86,720
| +1% | +$476K | ﹤0.01% | 1888 |
|
|
2022
Q3 | $33M | Buy |
6,649,331
+4,780,807
| +256% | +$21.8M | ﹤0.01% | 1883 |
|
|
2022
Q2 | $6.95M | Sell |
1,868,524
-4,891,782
| -72% | -$19.6M | ﹤0.01% | 2927 |
|
|
2022
Q1 | $37.9M | Buy |
6,760,306
+544,929
| +9% | +$3.34M | ﹤0.01% | 1932 |
|
|
2021
Q4 | $37.8M | Buy |
6,215,377
+897,597
| +17% | +$6.74M | ﹤0.01% | 2008 |
|
|
2021
Q3 | $51.8M | Buy |
5,317,780
+1,124,160
| +27% | +$12.4M | ﹤0.01% | 1780 |
|
|
2021
Q2 | $59.9M | Buy |
4,193,620
+1,861,048
| +80% | +$30.7M | ﹤0.01% | 1709 |
|
|
2021
Q1 | $55.4M | Buy |
2,332,572
+1,665,411
| +250% | +$43.2M | ﹤0.01% | 1667 |
|
|
2020
Q4 | $8.89M | Buy |
667,161
+133,847
| +25% | +$1.29M | ﹤0.01% | 2698 |
|
|
2020
Q3 | $3.7M | Buy |
533,314
+23,973
| +5% | +$239K | ﹤0.01% | 2931 |
|
|
2020
Q2 | $6.25M | Buy |
509,341
+498,841
| +4,751% | +$2.82M | ﹤0.01% | 2651 |
|
|
2020
Q1 | $30K | Sell |
10,500
-3,520
| -25% | -$17.6K | ﹤0.01% | 3684 |
|
|
2019
Q4 | $53K | Sell |
14,020
-7,925
| -36% | -$13.5K | ﹤0.01% | 3720 |
|
|
2019
Q3 | $27K | Buy |
21,945
+564
| +3% | +$700 | ﹤0.01% | 3752 |
|
|
2019
Q2 | $22K | Sell |
21,381
-392,755
| -95% | -$453K | ﹤0.01% | 3770 |
|
|
2019
Q1 | $654K | Buy |
414,136
+2,692
| +0.7% | +$3.38K | ﹤0.01% | 3411 |
|
|
2018
Q4 | $477K | Sell |
411,444
-653
| -0.2% | -$1.49K | ﹤0.01% | 3455 |
|
|
2018
Q3 | $1.52M | Buy |
412,097
+2,868
| +0.7% | +$9.07K | ﹤0.01% | 3333 |
|
|
2018
Q2 | $1.25M | Buy |
409,229
+7,774
| +2% | +$28.8K | ﹤0.01% | 3372 |
|
|
2018
Q1 | $1.56M | Buy |
401,455
+33,126
| +9% | +$145K | ﹤0.01% | 3249 |
|
|
2017
Q4 | $1.65M | Buy |
368,329
+11,991
| +3% | +$56.8K | ﹤0.01% | 3242 |
|
|
2017
Q3 | $1.95M | Buy |
356,338
+15,331
| +4% | +$94.5K | ﹤0.01% | 3215 |
|
|
2017
Q2 | $2.59M | Buy |
341,007
+117,946
| +53% | +$510K | ﹤0.01% | 3028 |
|
|
2017
Q1 | $791K | Buy |
223,061
+29,610
| +15% | +$146K | ﹤0.01% | 3317 |
|
|
2016
Q4 | $1.1M | Buy |
193,451
+40,848
| +27% | +$273K | ﹤0.01% | 3257 |
|
|
2016
Q3 | $1.19M | Buy |
152,603
+17,333
| +13% | +$130K | ﹤0.01% | 3147 |
|
|
2016
Q2 | $843K | Buy |
135,270
+10,640
| +9% | +$82.6K | ﹤0.01% | 3307 |
|
|
2016
Q1 | $1.02M | Buy |
124,630
+23,497
| +23% | +$221K | ﹤0.01% | 3207 |
|
|
2015
Q4 | $1.75M | Buy |
101,133
+58,708
| +138% | +$871K | ﹤0.01% | 3043 |
|
|
2015
Q3 | $485K | Buy |
+42,425
| New | +$926K | ﹤0.01% | 3340 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
State Street's IBRX Position: Q1 2026 in Review
State Street increased its ImmunityBio (IBRX) stake by 7.6% in Q1 2026, buying an estimated $8.57M and bringing the position to 17,708,103 shares worth $136M. The position accounts for ﹤0.01% of the portfolio, ranked #1191.
State Street first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- State Street held 17,708,103 shares of ImmunityBio worth $136M as of Q1 2026.
- State Street bought 1,252,400 ImmunityBio shares in Q1 2026, an estimated $8.57M.
- ImmunityBio made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1191 holding.
- State Street first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.